| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/28/2010 | CA2731574A1 Isosorbide nitrates having vasodilating activity |
| 01/28/2010 | CA2731573A1 Therapeutic agent for migraine |
| 01/28/2010 | CA2731544A1 Aminophosphinic derivatives that can be used in the treatment of pain |
| 01/28/2010 | CA2731503A1 Taxane compounds for treating eye disease |
| 01/28/2010 | CA2731501A1 Transdermal pharmaceutical compositions comprising danazol |
| 01/28/2010 | CA2731498A1 Tri-cyclic pyrazolopyridine kinase inhibitors |
| 01/28/2010 | CA2731496A1 Pyrazolopyridine kinase inhibitors |
| 01/28/2010 | CA2731455A1 Methods of administering topical antifungal formulations for the treatment of fungal infections |
| 01/28/2010 | CA2731451A1 Pyrazolopyridine kinase inhibitors |
| 01/28/2010 | CA2731445A1 Topical anti-inflammatory combination |
| 01/28/2010 | CA2731432A1 Tri-cyclic pyrazolopyridine kinase inhibitors |
| 01/28/2010 | CA2731429A1 Large substituent, non-phenolic amine opioids |
| 01/28/2010 | CA2731356A1 Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments |
| 01/28/2010 | CA2731312A1 Pharmaceutical formulation for treating the upper digestive tract |
| 01/28/2010 | CA2731295A1 Novel substituted sulfamide derivatives |
| 01/28/2010 | CA2731271A1 Stable aqueous solution composition containing sulfonamide compound |
| 01/28/2010 | CA2731254A1 Process for the preparation of esomeprazole magnesium in a stable form |
| 01/28/2010 | CA2731224A1 Inhibitors of the plasmodial surface anion channel as antimalarials |
| 01/28/2010 | CA2731190A1 Pyridinyl modulators of .gamma.-secretase |
| 01/28/2010 | CA2731146A1 3,4-diarylpyrazoles as protein kinase inhibitors |
| 01/28/2010 | CA2730762A1 Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| 01/28/2010 | CA2730757A1 Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| 01/28/2010 | CA2730751A1 Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
| 01/28/2010 | CA2730599A1 Therapeutic agent for chronic renal failure |
| 01/28/2010 | CA2730517A1 Heterocyclic antiviral compounds |
| 01/28/2010 | CA2730500A1 Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid deri vatives useful in the treatment of autoimmune and inflammatory disorders |
| 01/28/2010 | CA2730499A1 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 01/28/2010 | CA2730288A1 Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof |
| 01/28/2010 | CA2730208A1 1,1'-diadamantyl carboxylic acids, medicaments containing such compounds and their use |
| 01/28/2010 | CA2730005A1 High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms |
| 01/28/2010 | CA2729998A1 Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 01/28/2010 | CA2728932A1 Pyrrolobenzodiazepines |
| 01/28/2010 | CA2728629A1 Adamantyl diamide derivatives and uses of same |
| 01/28/2010 | CA2728480A1 4,5-dihydro-oxazol-2-yl derivatives |
| 01/28/2010 | CA2728357A1 Device and method for controlling insects |
| 01/28/2010 | CA2719847A1 Inhibitors of janus kinases |
| 01/28/2010 | CA2690828A1 Composition containing microrna-21 inhibitor for enhancing radiation sensitivity |
| 01/27/2010 | EP2147978A2 N-Terminally truncated HER-2/NEU protein as a cancer prognostic indicator |
| 01/27/2010 | EP2147927A2 Use of 131i-tm-601 for the diagnosis and treatment of gliomas |
| 01/27/2010 | EP2147924A1 Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| 01/27/2010 | EP2147922A1 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| 01/27/2010 | EP2147918A1 Process for the preparation of S-omeprazole magnesium in a stable form |
| 01/27/2010 | EP2147915A1 New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them |
| 01/27/2010 | EP2147914A1 Aminodihydrothiazine derivatives substituted with cyclic groups |
| 01/27/2010 | EP2147913A1 Styrylquinolines, their process of preparation and their therapeutic uses |
| 01/27/2010 | EP2147912A1 Styrylquinolines, their process of preparation and their therapeutic uses |
| 01/27/2010 | EP2147910A1 Novel lipid compounds |
| 01/27/2010 | EP2147681A1 Compositions and methods for treating lysosomal storage disease |
| 01/27/2010 | EP2147674A1 Transdermal pharmaceutical compositions comprising danazol |
| 01/27/2010 | EP2147673A1 Modulation of prostaglandin/cyclooxygenase metabolic pathways |
| 01/27/2010 | EP2147672A1 Cytotoxic t cell activator comprising ep4 agonist |
| 01/27/2010 | EP2147671A1 The composition comprising l-carnitine or derivatives thereof and its use |
| 01/27/2010 | EP2147670A1 Chemically stable compositions of 4-hydroxy tamoxifen |
| 01/27/2010 | EP2147117A2 Methods of diagnosing alzheimer's disease and markers identified by set association |
| 01/27/2010 | EP2147103A2 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| 01/27/2010 | EP2147014A1 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
| 01/27/2010 | EP2147011A2 Method for inhibiting scavenger receptor-a and increasing immune response to antigens |
| 01/27/2010 | EP2146997A1 Substituted furo[2,3-b]pyridine derivatives as cannabinoid-1 receptor modulators |
| 01/27/2010 | EP2146996A1 Xanthine compounds having a positive allosteric gabab receptor modulator effect |
| 01/27/2010 | EP2146991A2 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 01/27/2010 | EP2146989A1 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases |
| 01/27/2010 | EP2146988A1 New 4,8-diphenyl-polyazanaphthalene derivatives |
| 01/27/2010 | EP2146986A1 Diphenyl-dihydro-imidazopyridinones |
| 01/27/2010 | EP2146985A1 Heterocyclic compounds and their methods of use |
| 01/27/2010 | EP2146984A1 Hepatitis c virus inhibitors |
| 01/27/2010 | EP2146983A1 Pyrazoles useful in the treatment of inflammation |
| 01/27/2010 | EP2146982A2 Aminopyrimidines useful as kinase inhibitors |
| 01/27/2010 | EP2146980A2 Histamine h3 receptor ligands comprising a cyclobutoxy group |
| 01/27/2010 | EP2146979A1 A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701 |
| 01/27/2010 | EP2146978A1 Imatinib production process |
| 01/27/2010 | EP2146976A2 Compositions of tolperisone |
| 01/27/2010 | EP2146974A1 N- hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine 2 ethansulfonic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same |
| 01/27/2010 | EP2146971A1 Novel benzamidine derivatives useful as potassium channel modulators |
| 01/27/2010 | EP2146968A1 Urea derivatives as glutaminyl cyclase inhibitors |
| 01/27/2010 | EP2146967A2 Tetrahydroindole and tetrahydroindazole derivatives |
| 01/27/2010 | EP2146963A2 Dual-acting antihypertensive agents |
| 01/27/2010 | EP2146962A2 Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals |
| 01/27/2010 | EP2146961A1 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
| 01/27/2010 | EP2146959A1 Vanilloid receptor ligands and the use thereof for the production of pharmaceuticals |
| 01/27/2010 | EP2146958A1 Process for the preparation of form a of tegaserod |
| 01/27/2010 | EP2146957A1 Quaternary ammonium compounds useful as muscarinic receptor antagonists |
| 01/27/2010 | EP2146952A1 N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
| 01/27/2010 | EP2146951A2 Novel rar receptor agonist ligands and use thereof in human medicine and cosmetics |
| 01/27/2010 | EP2146948A1 Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
| 01/27/2010 | EP2146946A2 Stereoisomeric propofol therapeutic compounds |
| 01/27/2010 | EP2146779A1 Sulfonyl amide derivatives for the treatment of abnormal cell growth |
| 01/27/2010 | EP2146753A2 18f fluoro-benzoyl labelled biological active compounds as diagnostic imaging agents as well as benzotriazol-1-yloxy-benzoyl , 2,5-dioxo-pyrrolidin-1-yloxy)benzoyl and trimethylammonio-benzoyl precursers thereof |
| 01/27/2010 | EP2146750A1 Stabilized suspension |
| 01/27/2010 | EP2146748A1 Macrophage transfection method |
| 01/27/2010 | EP2146740A1 Methods of controlling tumorigenesis and diagnosing the risk thereof |
| 01/27/2010 | EP2146739A2 Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments |
| 01/27/2010 | EP2146736A2 Modulators of vegf splicing as pro- and anti-angiogenic agents |
| 01/27/2010 | EP2146735A1 Sparc and methods of use thereof |
| 01/27/2010 | EP2146727A1 High viscosity macromolecular compositions for treating ocular conditions |
| 01/27/2010 | EP2146726A1 Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
| 01/27/2010 | EP2146725A1 A composition for regulating cellular senescence comprising n-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide |
| 01/27/2010 | EP2146724A2 Role of hedgehog signaling in atherosclerosis and cardiovascular disease |
| 01/27/2010 | EP2146723A1 Means and methods for counteracting protein aggregation |
| 01/27/2010 | EP2146722A1 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| 01/27/2010 | EP2146721A2 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival |